Moberg Pharma´s Interim report January - March 2023
REGISTRATION PROCESS ONGOING, 120-DAY REPORT AND 145-DAY QUESTIONS RECEIVEDFIRST QUARTER (JAN-MAR 2023) · EBITDA SEK -6.1 million (-4.8) · Operating profit (EBIT) SEK -6.7 million (-5.4) · Profit after tax SEK -5.0 million (-4.4) · Total profit SEK -5.0 million (-4.4) · Diluted earnings per share SEK -0.05 (-0.10) · Cash and cash equivalents amounted to SEK 84.5 million (73.4) SIGNIFICANT EVENTS IN THE FIRST QUARTER · The company regains full rights to MOB-015 in Japan · The management team is strengthened with the addition of Jesper Lind, Head of Supply.